Use of imaging to assess patients with muscle disease

Current Opinion in Rheumatology

Volumn 16, Issue 6, 2004, Pages 678-683

  Scott, David L ^a,b   Kingsley, Gabrielle H ^a,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

Author keywords

Dermatomyositis; Magnetic resonance imaging; Magnetic resonance spectroscopy; Polymyositis; Ultrasound

Indexed keywords

ALENDRONIC ACID; GALLIUM 67; MEDRONATE TECHNETIUM TC 99M; PYROPHOSPHATE TECHNETIUM TC 99M;

BIOENERGY; CALCINOSIS; COST EFFECTIVENESS ANALYSIS; DERMATOMYOSITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; EXERCISE; HISTOPATHOLOGY; HUMAN; INCIDENCE; MUSCLE BIOPSY; MUSCLE DISEASE; MYOSITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OSSIFYING MYOSITIS; OSTEOMYELITIS; POLYMYOSITIS; PRIORITY JOURNAL; PYOMYOSITIS; REVIEW; SCINTIGRAPHY; TREATMENT OUTCOME; TREATMENT PLANNING; ULTRASOUND; X RAY;

HUMANS; MAGNETIC RESONANCE IMAGING; MUSCULAR DISEASES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 7044274718     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000141924.14317.8a     Document Type: Review

References (49)

1. Arrington ED, Miller MD: Skeletal muscle injuries. Orthop Clin North Am 1995, 26:411-422.
2. Baysal T, Elmali N, Kutlu R, Baysal O: The stone man: myositis (fibrodysplasia) ossificans progressive. Eur Radiol 1998, 8:479-481.
3. Patel SR, Olenginski TP, Perruquet JL, Harrington TM: Pyomyositis: clinical features and predisposing conditions. J Rheumatol 1997, 24:1734-1738.
4. Grigoriadis E, Fam AG, Starok M, Ang LC: Skeletal muscle infarction in diabetes mellitus. J Rheumatol 2000, 27:1063-1068.
5. Rider LG, Miller FW: Idiopathic inflammatory muscle disease: clinical aspects. Baillieres Best Pract Res Clin Rheumatol 2000, 14:37-54.
6. Askanas V, Engel WK: New advances in the understanding of sporadic inclusion-body myositis and hereditary inclusion-body myopathies. Curr Opin Rheumatol 1995, 7:486-496.
7. Griggs RC, Askanas V, DiMauro S, et al.: Inclusion body myositis and myopathies. Ann Neurol 1995, 38:705-713.
8. Oldorfs A, Larsson NG, Lindberg C, Holme E: Mitochondrial DNA deletions in inclusion body myositis. Brain 1993, 116:325-336.
9. Santorelli FM, Sciacco M, Tanji K, et al.: Multiple mitochondrial DNA deletions in sporadic inclusion body myositis: a study of 56 patients. Ann Neurol 1996, 39:789-795.
10. Sallum AM, Kiss MH, Sachetti S, et al.: Juvenile dermatomyositis: clinical, laboratorial, histological, therapeutical and evolutive parameters of 35 patients. Arq Neuropsiquiatr 2002, 60:889-899.
11. Fisler RE, Liang MG, Fuhlbrigge RC, et al.: Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002, 47:505-511.
12. Marie I, Fournet P, Janvresse A, et al.: Periarticular calcifications and arthropathy as the first manifestation of polymyositis. Clin Exp Rheumatol 2003, 21:681-682.
13. Cetin C, Sekir U, Yildiz Y, et al.: Chronic groin pain in an amateur soccer player. Br J Sports Med 2004, 38:223-224.
14. Ben Hamida KS, Hajri R, Kedadi H, et al.: Myositis ossificans circumscripta of the knee improved by alendronate. Joint Bone Spine 2004, 71:144-146.
15. Nakayama T, Saitoh Y, Yatabe K, et al.: Diagnosis of inflammatory myopathy; usefulness of 99mTc MDP scintigraphy and muscle MRI for determination of affected sites. Clin Neurol 1999, 39:1114-1117.
16. Lofberg M, Liewendahl K, Lamminen A, et al.: Antimyosin scintigraphy compared with magnetic resonance imaging in inflammatory myopathies. Arch Neurol 1998, 55:987-993.
17. Kane D, Grassi W, Sturrock R, Balint PV: Musculoskeletal ultrasound - a state of the art review in rheumatology. Part 2:Clinical indications for musculoskeletal ultrasound in rheumatology. Rheumatology (Oxford) 2004, 43:829-838. An excellent overview of musculoskeletal ultrasound.
18. Chason DP, Fleckenstein JL, Burns DK, Rojas G: Diabetic muscle infarction: radiologic evaluation. Skeletal Radiol 1996, 25:127-132.
19. Trusen A, Beissert M, Schultz G, et al.: Ultrasound and MRI features of pyomyositis in children. Eur Radiol 2003, 13:1050-1055. A detailed retrospective analysis of ultrasound and MRI findings in 12 children with pyomyositis.
20. Wilson DJ: Soft tissue and joint infection. Eur Radiol 2004 Jan 29, Epub ahead of print.
21. Tuerlinckx D, Bodart E, de Bilderling G, Nisolle JF: Pneumococcal psoas pyomyositis associated with complement deficiency. Pediatr Infect Dis J 2004, 23:371-373.
22. Flier S, Dolgin SE, Saphir RL, et al.: A case confirming the progressive stages of pyomyositis. J Pediatr Surg 2003, 38:1551-1553.
23. Wang JY, Lee LN, Hsueh PR, et al.: Tuberculous myositis: a rare but existing clinical entity. Rheumatology (Oxford) 2003, 42:836-840.
24. Kapur S, Brunet JA, McKendry RJ: Diabetic muscle infarction: case report and review. J Rheumatol 2004, 31:190-194. A definitive update of the literature on diabetic muscle infarction outlining experience in 116 cases.
25. Lentine KL, Guest SS: Diabetic muscle infarction in end-stage renal disease. Nephrol Dial Transplant 2004, 19:664-669.
26. Fraser DD, Frank JA, Dalakas M, et al.: Magnetic resonance imaging in the idiopathic inflammatory myopathies. J Rheumatol 1991, 18:1693-1700.
27. Fraser DD, Frank JA, Dalakas MC: Inflammatory myopathies: MR imaging and spectroscopy. Radiology 1991, 179:341-344.
28. Kaufman LD, Gruber BL, Gerstman DP, Kaell AT: Preliminary observations on the role of magnetic resonance imaging for polymyositis and dermatomyositis. Ann Rheum Dis 1987, 46:569-572.
29. Lamminen AE: Magnetic resonance imaging of primary skeletal muscle diseases: patterns of distribution and severity of involvement. Br J Radiol 1990, 63:946-950.
30. Fujino H, Kobayashi T, Goto I, Onitsuka H: Magnetic resonance imaging of the muscles in patients with polymyositis and dermatomyositis. Muscle Nerve 1991, 14:716-720.
31. Chung YL, Smith EC, Williams SCR, et al.: In vivo proton magnetic resonance spectroscopy in polymyositis and dermatomyositis: A preliminary study. Eur J Med Res 1997, 2:483-487.
32. Keim DR, Hernandez RJ, Sullivan DB: Serial magnetic resonance imaging in juvenile dermatomyositis. Arthritis Rheum 1991, 34:1580-1584.
33. Hernandez RJ, Keim DR, Chenevert TL, et al.: Fat-suppressed MR imaging of myositis. Radiology 1992, 182:217-219.
34. Kimball AB, Summers RM, Turner M, et al.: Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis: implications for diagnosis and therapy. Arthritis Rheum 2000, 43:1866-1873.
35. Powell T, Brennan D, Lynch T, et al.: Whole-body MR imaging in the diagnosis of polymyositis. AJR Am J Roentgenol 2002, 179:967-971.
36. Lam WW, Chan H, Chan YL, et al.: MR imaging in amyopathic dermatomyositis. Acta Radiol 1999, 40:69-72.
37. Schweitzer ME, Fort J: Cost-effectiveness of MR imaging in evaluating polymyositis. Am J Roentgenol 1995, 165:1469-1471.
38. Kiely PD, Heron CW, Bruckner FE: Presentation and management of idiopathic inflammatory muscle disease: four case reports and commentary from a series of 78 patients. Rheumatology (Oxford) 2003, 42:575-582.
39. Maillard SM, Jones R, Owens C et al.: Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis. Rheumatology (Oxford) 2004, 43:603-608. A detailed evaluation of MRI in juvenile dermatomyositis. Ten children with active myositis, 10 with inactive disease, and 20 healthy children were studied. The MRI T2 relaxation times were significantly increased in active myositis compared with inactive disease and healthy children. There were also good correlations between the MRI scores and the measures of muscle strength and function; however, there was no correlation between the MRI and muscle enzymes.
40. Dion E, Cherin P, Payan C, et al.: Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis. J Rheumatol 2002, 29:1897-1906.
41. Hengstman GJ: Magnetic resonance imaging criteria to differentiate inclusion body myositis from polymyositis. J Rheumatol 2003, 30:1892.
42. Mastaglia FL, Garlepp MJ, Phillips BA, Zilko PJ: Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve 2003, 27:407-425.
43. Dalakas MC, Hohlfeld R: Polymyositis and dermatomyositis. Lancet 2003, 362:971-982.
44. Isenberg DA, Allen E, Farewell V, et al.: International Myositis and Clinical Studies Group (IMACS). International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004, 43:49-54.
45. 31P MRS was used to assess short-term alterations of metabolic dynamics during muscular exercise in 10 patients with dermatomyositis and 18 healthy subjects. In five short (1 minute) cycles of submaximal exercise Pi/PCr ratios during exercise increased in patients and controls. They rapidly returned to baseline values in the controls, but both Pi and PCr remained above baseline values in patients and resulted in irregular Pi/PCr ratios.
46. Chung YL, Wassif WS, Bell JD, et al.: Urinary levels of creatine and other metabolites in the assessment of polymyositis and dermatomyositis. Rheumatology (Oxford) 2003, 42:298-303.
47. Brosseau OE, Mahdjoub R, Seurin MJ, et al.: Kinetics of anaerobic metabolism in human skeletal muscle: influence of repetitive high-intensity exercise on sedentary dominant and non-dominant forearm. A 31P NMR study. Biochimie 2003, 85:885-890.
48. Schocke MF, Esterhammer R, Kammerlander C, et al.: High-energy phosphate metabolism during incremental calf exercise in humans measured by 31 phosphorus magnetic resonance spectroscopy (31 PMRS). Magn Reson Imaging 2004, 22:109-115.
49. Smith SA, Montain SJ, Zientara GP, Fielding RA: Use of phosphocreatine kinetics to determine the influence of creatine on muscle mitocriondrial respiration: an in vivo 31P-MRS study of oral creatine ingestion. J Appl Physiol 2004, 96:2288-2292.